NDAORALSOLUTION
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
VOSTALLY (ramipril) by Teva is angiotensin-converting enzyme inhibitors [moa]. Approved for hypertension, heart failure, diabetes mellitus and 1 more indications. First approved in 2025.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOSTALLY (ramipril) is an ACE inhibitor oral solution approved July 2025 for treating hypertension, heart failure, diabetes, and acute myocardial infarction. It works by blocking angiotensin-converting enzyme to reduce vasoconstriction and lower blood pressure. The oral solution formulation represents a differentiated delivery mechanism in a crowded ACE inhibitor class.
Launch13.3 years to LOE
Early-stage launch phase with zero competitive pressure offers significant opportunity for market capture, but team scaling depends on payer adoption and uptake velocity.
Mechanism of Action
Angiotensin-converting Enzyme Inhibitors
Pharmacologic Class:
Angiotensin Converting Enzyme Inhibitor
Indications (4)
Worked on VOSTALLY at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.